药物研发中在研药物致肝损伤潜力的评估
本文综述了药物研发过程中评估在研药物致药物性肝损伤(DILI)潜力的方法,包括临床前体外与动物实验、定量系统毒理学等计算机模拟方法、临床试验中的患者选择与监测策略,以及监管机构在新药申请中对DILI风险的审评方式,并指出这些方法已显著减少肝毒性药物的上市批准,但在遗传药物、生物制剂和免疫疗法等领域仍面临挑战。
要点
- 临床前筛查方法趋于过度敏感且阳性预测值不足。
- 临床试验中通过患者选择、DILI监测及停药标准管理风险。
- 定量系统毒理学提供有前景的补充性计算机模拟方法。
核心结论
- 现有方法已显著减少最终与肝毒性相关的药物上市批准,但在遗传药物、生物制剂和免疫疗法的临床前及临床开发各阶段识别DILI风险仍存在许多挑战。
研究设计与样本
- 综述,讨论当前临床前、计算机模拟和临床开发中筛查在研药物DILI潜力的方法,并高层次描述监管机构在新药申请中评估DILI风险的方式。
主要发现
- 临床前检测通常包括多种体外试验和体内动物实验,之后化合物才进入首次人体1期试验。
- 过去二十年临床前筛查有新进展,但这些方法趋于过度敏感且阳性预测值不足。
- 临床试验中通过与监管机构密切协作,采用患者选择、DILI监测范式以及药物中断和停药标准来管理在研药物的DILI潜力和受试者风险。
- 定量系统毒理学通过多层面系统生物学提供有前景的补充性计算机模拟方法,预测化合物的DILI风险。
- 药物开发商提交新药申请时,监管机构以结构化方式审评临床前和临床试验数据以评估DILI风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 临床前筛查方法趋于过度敏感且阳性预测值不足。
- 在遗传药物、生物制剂和免疫疗法的临床前及临床开发各阶段识别DILI风险仍存在许多挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DILI is rare in clinical practice, but when it occurs, it can lead to acute liver failure and death. Drug developers and regulators undertake a series of steps to identify the DILI potential of a medication before it is approved for marketing. Preclinical testing by drug developers typically involves a multitude of in vitro assays and in vivo animal experiments before a compound is moved into first-in-human phase 1 testing. Over the last 2 decades, there have been a number of advances in preclinical screening for DILI potential of a new chemical entity, but these approaches tend to be overly sensitive with insufficient positive predictive value. Once in clinical trials, the DILI potential of an investigational agent and risks to a participant are carefully managed through patient selection, DILI monitoring paradigms, and drug interruption and discontinuation criteria, in close concert with the regulators. Recent developments in quantitative systems toxicology offer promising and complementary in silico approaches to predict the compound's risk for DILI via multifaceted systems biology. When a drug developer submits a New Drug Application for marketing approval, regulators review the preclinical and clinical trial data in a structured fashion to assess the DILI risk. While these approaches have been successful in dramatically reducing the marketing approval of medications eventually associated with hepatotoxicity, many challenges remain in identifying the risk for DILI during preclinical and early-to-late clinical development stages for genetic medicines, biological agents, and immunotherapies. In this review, we discuss current preclinical, in-silico, and clinical development approaches to screen for the DILI potential of an investigational agent and provide a high-level description of regulators' approach for assessing DILI risk in a New Drug Application.
引用
- Chalasani N, Hayashi PH, Luffer-Atlas D, et al. Assessment of liver injury potential of investigational medicines in drug development. Hepatology. 2025. PMID: 39999469. doi:10.1097/HEP.0000000000001281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。